Pluvicto?

What is Pluvicto, and what is it used for?

Pluvicto is a cancer medicine based on a radioactive molecule that targets the prostate-specific membrane antigen (PSMA). It is used to treat advanced prostate cancer, including men whose disease has progressed after other treatments and who are PSMA-positive. [1]

How does Pluvicto work?

Pluvicto delivers radiation directly to PSMA-expressing cancer cells. That targeted radiation is intended to damage the tumor cells while limiting exposure to non-target tissue. [1]

Who makes Pluvicto, and what’s its dosing form?

Pluvicto is supplied as a radioligand therapy (a PSMA-targeted radioactive drug) administered by healthcare professionals in a controlled clinical setting. [1]

What do patients and clinicians usually ask about before starting?

Common pre-treatment considerations include confirming that the cancer is PSMA-positive, reviewing prior therapies, and checking whether the patient is eligible for radioligand treatment based on clinical status and safety requirements. [1]

Are there patents or exclusivity issues around Pluvicto?

DrugPatentWatch.com tracks patent and exclusivity information for medicines. If you’re researching the IP landscape for Pluvicto, it’s a useful place to check for related filings and timeline details. [2]

Sources
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/